RT Journal Article
SR Electronic
T1 Intravenous probenecid loading
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP 992
OP 992
DO 10.1212/WNL.26.10.992
VO 26
IS 10
A1 KARTZINEL, RONALD
A1 EBERT, MICHAEL H.
A1 CHASE, THOMAS N.
YR 1976
UL http://n.neurology.org/content/26/10/992.abstract
AB Probenecid blocks the active transport from cerebrospinal fluid to blood of homovanillic acid and 5-hydroxyindoleacetic acid, thus increasing cerebrospinal fluid levels of these products of central monoamine metabolism. The half-life in plasma of probenecid given as a single intravenous infusion (40 mg per kilogram of body weight) to patients with either Huntington's chorea or Parkinson's disease averaged about 6.6 hours. In cerebrospinal fluid, peak values for homovanillic acid and 5-hydroxyindoleacetic acid occurred in samples collected 8 hours after the 1 -hour probenecid infusion was started. Even after 4 hours, however, levels of both monoamine metabolites were significantly increased. There was a positive correlation between cerebrospinal fluid levels of probenecid and the increase in 5-hydroxyindoleacetic acid but not homovanillic acid. Compared with the oral administration of probenecid, the intravenous infusion technique produced more consistent elevations in plasma and cerebrospinal fluid probenecid levels, greater increases in cerebrospinal fluid homovanillic acid values, and fewer gastrointestinal side effects.